Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland.
Mesoblast stock last closed at $7.50, up 2.88% from the previous day, and has increased 13.64% in one year. It has overperformed other stocks in the Biotechnology industry by 0.32 percentage points. Mesoblast stock is currently +365.84% from its 52-week low of $1.61, and -26.76% from its 52-week high of $10.24.
As of May 3, 2024, there are 1.01B MESO shares outstanding. The market cap of MESO is $761.10M. In the last 24 hours, 282,870 MESO shares were traded.
You will need a brokerage account to access the NASDAQ market and buy MESO shares.
Based on our analysis, eToro is the best stock brokerage. Here's why:
Get $10 towards your purchase of stock by opening an account with eToro today.
Open eToro AccountNow that you've selected the right brokerage, you'll need to fill out some personal details so you are able to buy MESO today.
Now that you have filled out your info on the best stock investing app, you need to deposit funds:
Watch the tutorial below for more details transferring funds into your new brokerage account.
After you have selected the best place to buy Mesoblast stock, it's important to evaluate their stock before you buy, so you actually comprehend the risk as well as the upside.
WallStreetZen was built to help everyday investors perform more in-depth fundamental analysis quickly.
You can view all of the due diligence checks on MESO's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge MESO's intrinsic value.
Using relative valuations ratios:
You can access additional valuation analysis on MESO's stock here.
You can dive deeper into what analysts are saying on the Mesoblast stock forecast page.
Last year, MESO revenue was $7.25M. During the last five year, MESO's revenue has increased by -14.93% per year. This was slower than the Biotechnology industry average of 29.63%.
Dig into MESO's earnings and revenue performance here.
Over the past 12 months, insiders at MESO have not bought or sold any shares.
Learn more about who owns MESO stock here.
No, Mesoblast doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
You have two main options:
Press the Open Trade button and eToro will place the order.
If you require additional assistance buying stocks on eToro, watch the helpful video below:
Now that you own some shares in MESO, you'll want to stay up-to-date on your investment.
Make a watchlist to get notified of important updates regarding your MESO stock.
To reiterate, here are the 6 steps to buy stock in Mesoblast:
If you are looking for a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to track your investment in Mesoblast, get started below.